TRILIPIX Drug Patent Profile
✉ Email this page to a colleague
When do Trilipix patents expire, and when can generic versions of Trilipix launch?
Trilipix is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.
This drug has nineteen patent family members in eleven countries.
The generic ingredient in TRILIPIX is choline fenofibrate. There are one hundred and two drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the choline fenofibrate profile page.
DrugPatentWatch® Generic Entry Outlook for Trilipix
There are two Paragraph IV patent challenges for this drug. This may lead to patent invalidation or a license for generic production.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRILIPIX?
- What are the global sales for TRILIPIX?
- What is Average Wholesale Price for TRILIPIX?
Summary for TRILIPIX
International Patents: | 19 |
US Patents: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 182 |
Clinical Trials: | 9 |
Patent Applications: | 2,599 |
Drug Prices: | Drug price information for TRILIPIX |
What excipients (inactive ingredients) are in TRILIPIX? | TRILIPIX excipients list |
DailyMed Link: | TRILIPIX at DailyMed |
Paragraph IV (Patent) Challenges for TRILIPIX
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
TRILIPIX | Delayed-release Capsules | choline fenofibrate | 45 mg | 022224 | 1 | 2009-09-02 |
TRILIPIX | Delayed-release Capsules | choline fenofibrate | 135 mg | 022224 | 1 | 2009-09-01 |
US Patents and Regulatory Information for TRILIPIX
TRILIPIX is protected by one US patents.
Patents protecting TRILIPIX
Salts of fenofibric acid and pharmaceutical formulations thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224-001 | Dec 15, 2008 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Abbvie | TRILIPIX | choline fenofibrate | CAPSULE, DELAYED RELEASE;ORAL | 022224-002 | Dec 15, 2008 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for TRILIPIX
See the table below for patents covering TRILIPIX around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Mexico | PA05005736 | FORMULACION QUE COMPRENDE ACIDO FENOFIBRICO, UNA SAL FISIOLOGICAMENTE ACEPTABLE O DERIVADO DEL MISMO. (FORMULATION COMPRISING FENOFIBRIC ACID, A PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE THEREOF.) | ⤷ Sign Up |
Spain | 2286486 | ⤷ Sign Up | |
Russian Federation | 2356549 | КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ФЕНОФИБРИНОВУЮ КИСЛОТУ, ЕЕ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ ИЛИ ПРОИЗВОДНОЕ (COMPOSITION CONTAINING PHENOFIBRIN ACID, ITS PHYSIOLOGICALLY ACCEPTABLE SALT OR DERIVATIVE) | ⤷ Sign Up |
Australia | 2010249244 | Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof | ⤷ Sign Up |
China | 100473378 | ⤷ Sign Up | |
Russian Federation | 2500398 | КОМПОЗИЦИЯ, ВКЛЮЧАЮЩАЯ ФЕНОФИБРИНОВУЮ КИСЛОТУ ИЛИ ЕЕ ФИЗИОЛОГИЧЕСКИ ПРИЕМЛЕМУЮ СОЛЬ, И КАПСУЛА, ВКЛЮЧАЮЩАЯ КОМПОЗИЦИЮ (COMPOSITION CONTAINING FENOFIBRIC ACID OR PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND CAPSULE CONTAINING COMPOSITION) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TRILIPIX
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1758590 | 300907 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DEOXYCHOLINEZUUR NATRIUMZOUT; REGISTRATION NO/DATE: RVG120593 20170804 |
1746976 | 2017C/027 | Belgium | ⤷ Sign Up | PRODUCT NAME: LE SEL DE SUCROSOFATE D'IRINOTECAN, PAR EXEMPLE LE SEL DE SUCROSOFATE D'IRINOTECAN INCORPORE DANS UN LIPOSOME MODIFIE PAR PEGYLATION, TEL QU'UN LIPOSOME COMPRENANT DE LA 1,2-DISTEAROYL-SN- PHOSPHATIDYLCHOLINE, DU CHOLESTEROL ET DU N- (OMEGA-METHOXY POLY (ETHYLENE GLYCOL) (POIDS MOLECULAIRE 2000) -OXYCARBONYL)-1,2-DISEEAROYLPHOSPHATIDYLETHANOLAMINE, PAR EXEMPLE DANS DES RAPPORTS MOLAIRES 3: 2: 0,015; OU COMME DEMANDE AUXILIAIRE, IRINOTECAN; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
1746976 | CA 2017 00030 | Denmark | ⤷ Sign Up | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL)...; REG. NO/DATE: EU/1 /16/1130 20161018 |
1746976 | LUC00026 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: IRINOTECAN SUCROSOFATE SALT, SUCH AS IRINOTECAN SUCROSOFATE SALT IN A PEGYLATED LIPOSOME, SUCH AS A LIPOSOME COMPRISING 1,2-DISTEAROYL-SN-PHOSPHATIDYLCHOLINE, CHOLESTEROL AND N-(OMEGA-METHOXY-POLY(ETHYLENE GLYCOL) (MOLECULAR WEIGHT 2000)-OXYCARBONYL)-1,2-DISTEAROYLPHOSPHATIDYL ETHANOLAMINE, E.G. IN THE MOLAR RATIO 3:2:0.015; AUTHORISATION NUMBER AND DATE: EU/1/16/1130 20161018 |
0050793 | 94C0009 | Belgium | ⤷ Sign Up | PRODUCT NAME: COLFOSCERIL PALMITAS (DIPALMITOYLPHOSPHATIDYLCHOLINE) (DPPC); NAT REG.: 251 IS 142 F 12; FIRST REG.: GB PL 0003/0283 19901214 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |